237 related articles for article (PubMed ID: 11502450)
1. Androgen deprivation therapy for patients with clinically localized (stages T1 to T3) prostate cancer and for patients with biochemical recurrence after radical prostatectomy.
Grossfeld GD; Small EJ; Lubeck DP; Latini D; Broering JM; Carroll PR
Urology; 2001 Aug; 58(2 Suppl 1):56-64. PubMed ID: 11502450
[TBL] [Abstract][Full Text] [Related]
2. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy.
Messing EM; Manola J; Yao J; Kiernan M; Crawford D; Wilding G; di'SantAgnese PA; Trump D;
Lancet Oncol; 2006 Jun; 7(6):472-9. PubMed ID: 16750497
[TBL] [Abstract][Full Text] [Related]
3. Intermittent androgen deprivation therapy in advanced prostate cancer.
Alva A; Hussain M
Curr Treat Options Oncol; 2014 Mar; 15(1):127-36. PubMed ID: 24395278
[TBL] [Abstract][Full Text] [Related]
4. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
5. Outcomes and Prognostic Factors in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Recurrence after Radical Prostatectomy.
Ravi P; Karnes RJ; Rangel LJ; Pagliaro LC
J Urol; 2018 Nov; 200(5):1075-1081. PubMed ID: 29709664
[TBL] [Abstract][Full Text] [Related]
6. A Phase II, Randomized, Multicenter Study Comparing 10 Months versus 4 Months of Degarelix Therapy in Prolonging the Off Treatment Interval in Men with Localized Prostate Cancer Receiving Intermittent Androgen Deprivation Therapy for Biochemical Recurrence following Radical Local Therapy.
Klotz L; Loblaw A; Siemens R; Ouellette P; Kapoor A; Kebabdjian M; Zhang L; Saad F;
J Urol; 2018 Aug; 200(2):335-343. PubMed ID: 29534997
[TBL] [Abstract][Full Text] [Related]
7. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline.
Loblaw DA; Virgo KS; Nam R; Somerfield MR; Ben-Josef E; Mendelson DS; Middleton R; Sharp SA; Smith TJ; Talcott J; Taplin M; Vogelzang NJ; Wade JL; Bennett CL; Scher HI;
J Clin Oncol; 2007 Apr; 25(12):1596-605. PubMed ID: 17404365
[TBL] [Abstract][Full Text] [Related]
8. Duration of neoadjuvant androgen deprivation therapy before radical prostatectomy and disease-free survival in men with prostate cancer.
Meyer F; Bairati I; Bédard C; Lacombe L; Têtu B; Fradet Y
Urology; 2001 Aug; 58(2 Suppl 1):71-7. PubMed ID: 11502453
[TBL] [Abstract][Full Text] [Related]
9. The role of induction androgen deprivation prior to radical prostatectomy.
Soloway MS; Watson R
Eur Urol; 1996; 29 Suppl 2():114-8. PubMed ID: 8717473
[TBL] [Abstract][Full Text] [Related]
10. Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series.
Gandaglia G; Fossati N; Karnes RJ; Boorjian SA; Colicchia M; Bossi A; Seisen T; Cozzarini C; Di Muzio N; Noris Chiorda B; Zaffuto E; Wiegel T; Shariat SF; Goldner G; Joniau S; Battaglia A; Haustermans K; De Meerleer G; Fonteyne V; Ost P; Van Poppel H; Montorsi F; Briganti A
Eur Urol; 2018 Apr; 73(4):512-518. PubMed ID: 29229176
[TBL] [Abstract][Full Text] [Related]
11. Endocrine treatment of prostate cancer.
Tammela T
J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
[TBL] [Abstract][Full Text] [Related]
12. Impact of adjuvant androgen deprivation therapy after radical prostatectomy on the survival of patients with pathological T3b prostate cancer.
Siddiqui SA; Boorjian SA; Blute ML; Rangel LJ; Bergstralh EJ; Karnes RJ; Frank I
BJU Int; 2011 Feb; 107(3):383-8. PubMed ID: 21265985
[TBL] [Abstract][Full Text] [Related]
13. Prostate-specific antigen screening trials and prostate cancer deaths: the androgen deprivation connection.
Haines IE; Gabor Miklos GL
J Natl Cancer Inst; 2013 Oct; 105(20):1534-9. PubMed ID: 24092918
[TBL] [Abstract][Full Text] [Related]
14. Select men benefit from androgen deprivation therapy delivered with salvage radiation therapy after prostatectomy.
Holliday EB; Kuban DA; Levy LB; Bolukbasi Y; Master P; Choi S; Nguyen Q; McGuire SE; Mahmood U; Frank SJ; Hoffman KE
Prostate Cancer Prostatic Dis; 2017 Dec; 20(4):389-394. PubMed ID: 28462945
[TBL] [Abstract][Full Text] [Related]
15. Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials.
Sciarra A; Abrahamsson PA; Brausi M; Galsky M; Mottet N; Sartor O; Tammela TL; Calais da Silva F
Eur Urol; 2013 Nov; 64(5):722-30. PubMed ID: 23628492
[TBL] [Abstract][Full Text] [Related]
16. Medical treatment for biochemical relapse after radiotherapy.
Quero L; Hennequin C
Cancer Radiother; 2014 Oct; 18(5-6):540-4. PubMed ID: 25179255
[TBL] [Abstract][Full Text] [Related]
17. Contemporary role of androgen deprivation therapy for prostate cancer.
Pagliarulo V; Bracarda S; Eisenberger MA; Mottet N; Schröder FH; Sternberg CN; Studer UE
Eur Urol; 2012 Jan; 61(1):11-25. PubMed ID: 21871711
[TBL] [Abstract][Full Text] [Related]
18. Stage T3 prostate cancer: a nonrandomized comparison between definitive irradiation and induction hormonal manipulation plus prostatectomy.
Corn BW; Valicenti RK; Mulholland SG; Hyslop T; Gomella L
Urology; 1998 May; 51(5):782-7. PubMed ID: 9610592
[TBL] [Abstract][Full Text] [Related]
19. Hormonal therapy options for patients with a rising prostate-specific antigen level after primary treatment for prostate cancer.
Hellerstedt B
Urology; 2003 Dec; 62 Suppl 1():79-86. PubMed ID: 14747045
[TBL] [Abstract][Full Text] [Related]
20. Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancer.
McKay RR; Gray KP; Hayes JH; Bubley GJ; Rosenberg JE; Hussain A; Kantoff PW; Taplin ME
Cancer; 2015 Aug; 121(15):2603-11. PubMed ID: 25903013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
